In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.
Understanding Recent Updates in IgA Nephropathy Pipeline
In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.
Advertisement
Advertisement
Trending on HCPLive
1
Looking Beyond TSH in Hypothyroidism Management, With Rosemarie Lajara, MD
2
Tips on Treating Hemangiomas and Molluscum Contagiosum in Children, With Lisa Swanson, MD
3
Key Diagnostic and Therapeutic Pearls for Connective Tissue Disease, With Michelle Min, MD
4
Identifying Confounders in Persistent Hypothyroidism Symptoms, With Rosemarie Lajara, MD
5